Treatment of Pediatric Acute Lymphoblastic Leukemia

Cooper, Stacy; Brown, Patrick

doi:10.1016/j.pcl.2014.09.006

Cited by 278 publications

(274 citation statements)

References 54 publications

Supporting

Mentioning

241

Contrasting

Unclassified

Order By: Relevance

“…For instance, among the drugs used for intensive multidrug chemotherapy to treat lymphoblastic leukemia and non-Hodgkin lymphoma, glucocorticoids are an essential component [2]. Indeed, owing to their ability to induce apoptosis in normal and neoplastic lymphoid cells, glucocorticoids are used to induce remission as well as during maintenance and continuing therapy of these malignant diseases [3]. Among the glucocorticoids available to treat these diseases, dexamethasone is the most commonly used since it has enhanced lymphoblast cytotoxicity [4] and improved central nervous system penetration leading to decreased risk of relapse [5].…”

Section: Introductionmentioning

confidence: 99%

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Binson

Venisse

Bacle³

et al. 2017

Pharmaceutical Technology in Hospital Pharmacy

View full text Add to dashboard Cite

AbstractBackgroundDexamethasone is commonly used to treat a wide variety of diseases including oncological disorders. The aim of this study was to propose a liquid formulation of dexamethasone. Therefore we have developed and assessed the stability of a 5 mg/mL dexamethasone oral suspension.MethodsA stability-indicating analytical method, using HPLC-UV, was developed and fully validated according to well-recognized international guidelines. The dexamethasone suspension was prepared using dexamethasone acetate powder and Ora-SweetResultsThe mean dexamethasone concentration of the compounded oral suspensions was equal to 5.07±0.17 mg/mL. No colour modifications, precipitate or suspending troubles was observed throughout the storage period and the pH of the oral suspensions was decreased slightly, from 4.41±0.01 to 4.20±0.02. According to the dexamethasone content determined by HPLC-UV, whatever storage condition was used, no significant degradation of dexamethasone occurred over the 60 days of the study period.ConclusionDexamethasone oral suspension prepared according to our conditions is stable over 60 days under regular storage temperatures (at 4±2 °C or at 21±3 °C).

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Binson

Venisse

Bacle³

et al. 2017

Pharmaceutical Technology in Hospital Pharmacy

View full text Add to dashboard Cite

show abstract

“…The classification is affected, for example, by age and white blood cells (WBC) count. 6,[28][29][30] The biochemical parameters obtained from ALL patient's charts, such as the risk (R), leukocytes (LE), blasts (BL), erythrocyte (E), hemoglobin (HG), and platelets (PL), are described in Table 2.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients

Almeida

Carrilho

Nixdorf

2017

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is a fatal disorder in most cases and is the most common cancer in young patients. ALL features an uncontrolled proliferation and maturation arrest of lymphoid progenitor cells (lymphoblast) in the bone marrow. An increase of reactive species production occurs in ALL with an involvement of oxidative stress (OS) and cellular damage. However, there is a lack of information about variations in young patients. The biomarker widely used to measure the OS is the main product of lipid peroxidation, the malondialdehyde (MDA). This biomarker, when evaluated by a chromatographic method and the data analyzed by multivariate analysis with other biochemical parameters of ALL patient charts, shows the distinction of healthy and ALL patients, and a great correlation with the risk of disease.

show abstract

“…The most important toxic effect of daunorubicin is cardiotoxicity [20]. Based on the ALL IC-BFM 2009 protocol, patients in the IR risk group received daunorubicin at a dose of 120 mg/m 2 and patients in the SR risk group received at a dose of 60 mg/m 2 ( Table 2).…”

Section: Discussionmentioning

confidence: 99%

Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol

Özdemir¹,

Kar²,

Turhan³

et al. 2017

OALib

View full text Add to dashboard Cite

The most common childhood cancer is acute lymphoblastic leukemia (ALL). Chemotherapy-associated hematological toxicity is well-known; however, there are few studies on hematologic toxicity incidence in children with ALL. We investigated the severity and incidence of hematologic toxicity during intense chemotherapy processes in children treated with ALL IC-BFM 2009 protocol. The study included 41 leukemic children in standard (SR) and intermediate risk (IR) groups treated between 2011 and 2015. During the induction period, the incidence of grade 4 toxicity in neutrophil count was 60%; the incidence of grade ≥ 3 toxicity in hemoglobin level was 34%; and the incidence of grade ≥ 3 toxicity in the platelet count was 51%. Deep neutropenia duration was 36.6 ± 12.7 (18 -68) days during the induction. 53% of the febrile neutropenic (FEN) episodes developed during the induction period. There were no statistical differences between SR and IR risk groups with respect to hemogram values deep neutropenia duration and the number of FEN episodes (p > 0.05, all). There was a positive correlation between the number of FEN episodes and duration of neutropenia. During the induction, the mean neutrophil count remained between 0.5 -1 × 10 9 /L. FEN episodes most commonly developed during the induction phase.

show abstract

Treatment of Pediatric Acute Lymphoblastic Leukemia

Cited by 278 publications

References 54 publications

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients

Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol

Contact Info

Product

Resources

About